[8] Metformin with GLP-RA & Long-term Outcomes: In patients with T2D, dual therapy with metformin and GLP-RA has demonstrated a 39% lower incidence of adiposity-related cancers (HR 0.61) and a 67% reduction in all-cause mortality (HR 0.33) compared to DPP-4 inhibitor use, with effects most pronounced in younger people with obesity
This can lead to a dull, persistent ache or generalized stiffness
Srligt vigtigt er det at involvere bde nrmeste overordnede og kolleger i lederteamet
It may compromise weight control where patients are taking GLP-1RAs and GLP-1/GIPRAs for this indication
Low-calorie (25 calories, 2g carbs, 2g fiber), built for performance and precision
Available from: Bossart M, Wagner M, Elvert R, Evers A, Hbschle T, Kloeckener T, et al